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Abstract
Objective. To assess the impact of Biﬁdobacterium lactis HN019 supplementation on whole gut transit time (WGTT) and
frequency of functional gastrointestinal (GI) symptoms in adults. Material and methods. We randomized 100 subjects
(mean age: 44 years; 64% female) with functional GI symptoms to consume a proprietary probiotic strain, B. lactis
HN019 (Fonterra Research Centre, Palmerston North, New Zealand), at daily doses of 17.2 billion colony forming units
(CFU) (highdose; n = 33), 1.8 billion CFU (low dose;n = 33),or placebo (n = 34)for14 days. The primary endpoint of WGTT
was assessed by X-ray on days 0 and 14 and was preceded by consumption of radiopaque markers once a day for 6 days. The
secondary endpoint of functional GI symptom frequency was recorded with a subject-reported numeric (1–100) scale before
and after supplementation. Results. Decreases in mean WGTT over the 14-day study period were statistically signiﬁcant in
the high dose group (49 ± 30 to 21 ± 32 h, p < 0.001) and the low dose group (60 ± 33 to 41 ± 39 h, p = 0.01), but not in the
placebo group (43 ± 31 to 44 ± 33 h). Time to excretion of all ingested markers was signiﬁcantly shorter in the treatment groups
versus placebo. Of the nine functional GI symptoms investigated, eight signiﬁcantly decreased in frequency in the high dose
group and seven decreased with low dose, while two decreased in the placebo group. No adverse events were reported in any
group. Conclusions. Daily B. lactis HN019 supplementation is well tolerated, decreases WGTT in a dose-dependent manner,
and reduces the frequency of functional GI symptoms in adults.
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Introduction
Functional gastrointestinal symptoms are non-
speciﬁc conditions with no identiﬁable structural or
biochemical cause [1] that often present concomi-
tantly [2]. The burden of functional gastrointestinal
symptoms is enormous as 42–69% of the population
report at least one of these disorders [3,4]. Treatment
is complicated by the non-speciﬁc presentation of
symptoms and by the fact that 75% of people do
not seek medical care when symptoms arise [5].
Therefore, management of functional gastrointestinal
symptoms is generally self-prescribed and directed at
treating individual symptoms. Despite acceptable
short-term symptom amelioration with over-the-
counter and homeopathic remedies in many cases,
no known treatment for functional gastrointestinal
symptoms is known to be safe and effective over
the long term.
Functional gastrointestinal symptoms are often
associated with disturbed intestinal transit. Whole
gut transit time (WGTT) signiﬁcantly inﬂuences
enterohepatic bile acid and steroid hormone circula-
tion as well as colonic pH and short-chain fatty
acid concentrations. Thus, it has been postulated
that functional gastrointestinal symptoms may be
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possibly bowel and breast cancer, when presenting
concomitantly with prolonged WGTT [6].
There is a clear need for treatments for functional
gastrointestinal symptoms and intestinal transit dis-
turbances that are safe, effective, and sustainable.
There is a growing consumer interest in functional
foods that can either promote the state of well being
and/or alleviate symptoms of certain medical condi-
tions. Probiotics may offer a promising alternative that
can be offered in a food or dietary supplement format
that is appealing to consumer preferences. Probiotics
have been extensively studied in the ﬁeld of gastro-
enterology and show potential for improving gastro-
intestinal symptoms and reducing WGTT [7–11].
However, the beneﬁt of probiotic supplementation
is believed to be strain speciﬁc and, therefore, clinical
trials are required to conﬁrm the safety and efﬁcacy of
individual strains.
Biﬁdobacterium lactis HN019 is a probiotic strain
for which many health beneﬁts have been established,
primarily related to immune enhancement [12].
B. lactis HN019 has also been shown to confer
beneﬁcial changes to the intestinal microﬂora [13]
although no studies have examined the effects of
B. lactis HN019 on functional gastrointestinal
symptoms or WGTT. This study was designed to
determine in a triple-blind, randomized, placebo-
controlled trial if dietary supplementation of
B. lactis HN019 can shorten WGTT and reduce
the frequency of functional gastrointestinal symptoms
in adults.
Material and methods
This single-center, triple-blind, randomized, placebo-
controlled, dose-ranging study was conducted at
Accurate Clinical Research (Houston, TX, USA).
All research procedures performed in this trial were
in strict accordance with a pre-deﬁned protocol that
was approved by all researchers. IntegReview Ethical
Review Board (Austin, TX, USA) approved the study
protocol on 11 August 2009 and participants pro-
vided informed consent before participation. This
study is registered under ClinicalTrials.gov number
NCT01171014.
Trial design
This was a single center, age- (25–50 years and
51–65 years) and gender-stratiﬁed, triple-blind, pla-
cebo-controlled, parallel-group, dose-ranging study
with a 1:1:1 allocation ratio among three study
groups.
Participants
Eligible subjects included males and females aged 25–
65 years; self report of stool type 2–4 on the Bristol
Stool Chart; and average of 1–3 bowel movements per
week. Exclusion criteria were use of any probiotic
product intended to improve gastrointestinal function
within the 2 weeks preceding study entry; major
chronic and uncontrolled systemic medical condi-
tions; severe gastrointestinal conditions known to
prolong WGTT; lactose intolerance; chronic diar-
rhea; gastric bypass surgery or lap band insertion
for weight loss; regular laxative use; and pregnant
or breast-feeding women.
Interventions
Study products (B. lactis HN019 and placebo pow-
ders) were supplied in capsules by Danisco USA, Inc.
(Madison, Wisconsin, USA). The capsules contained
either B. lactis HN019 at one of two dose levels
(17.2billioncolonyformingunits(CFU)or1.8billion
CFU) or placebo. The excipient used to adjust the
bacteria count per capsule and to serve as the placebo
was rice maltodextrin. All products were stored refrig-
erated at the study site until time of use and were
refrigerated by the participants throughout the sup-
plementation period. Product stability was monitored
during the study and no signiﬁcant reduction in viable
counts was observed.
A timeline of study activities is presented in
Figure 1. Following screening procedures, subjects
began a 1-week run-in period during which the nor-
mal diet was consumed without taking any study
product. During this period, subjects were asked to
discontinue the consumption of laxatives, dietary
ﬁber supplements, probiotics including B. lactis,
and any other products that might affect WGTT.
Following the run-in period, subjects were random-
ized into one of three study groups: 17.2 billion
CFU B. lactis HN019 per day (high dose, n = 33),
1.8 billion CFU B. lactis HN019 per day (low dose,
n = 33), or placebo (n = 34). Over14 consecutive days,
study products were consumed once daily with break-
fast by adding the entire contents of a capsule to
commercial yogurt that was free from probiotics
(product contained standard yogurt starter cultures
Lactobacillus bulgaricus and Streptococcus thermophilus).
The classic single ﬁlm estimate was utilized to
quantify WGTT [14]. Each subject ingested 24
radiopaque markers per day for six consecutive
days prior to abdominal X-rays on days 0 and 14.
The number of markers present in the right, left, and
rectosigmoid colon were summed to yield a total
marker count. Marker counts were identiﬁed by a
1058 P. A. Waller et al.single board-certiﬁed radiologist (Gulf Coast MRI &
Diagnostics, Houston, TX, USA) who was blinded to
subject treatment assignment.
Outcomes
The primary endpoint of WGTT was assessed by
abdominal X-ray on days 0 and 14. A food frequency
questionnaire was completed on days 0 and 14 to
determine diet consistency during the study period.
Data were collected on the frequency of ingestion of
17 food categories over the previous week including
dairy products (milk, cheese, yogurt, and ice cream);
meat, ﬁsh, or poultry; eggs; peanut butter or nuts;
citrus fruits or juices; dark green leafy or deep orange
vegetables; other fruits or vegetables; bread, cereal,
rice, orpasta; sweets; salty snacks; soft drinks; alcohol;
coffee or tea; and fast food. The frequency of food
consumption in each category was self-rated on a
5-point Likert scale (0 = never, 1 = seldom, 2 = 2–
3 times per week, 3 = once a day, and 4 = more than
once a day). A questionnaire was administered on
study days 0 and 14 to evaluate the frequency of nine
upper (vomiting, regurgitation, abdominal pain, nau-
sea, and gurgling) and lower (constipation, diarrhea,
irregular bowel movements, and ﬂatulence) gastroin-
testinal symptoms experienced over the previous
week. The frequency of each symptom was subject-
reported using a numeric scale anchored at 1 (never)
and 100 (always). Adverse events were deﬁned as any
untoward medical occurrence that occurred during
the trial, regardless of the relationship with the admin-
istered study product.
Sample size
A total required sample size of 100 subjects equally
distributed among the three treatment groups was
calculated based on an anticipated 33% reduction
in WGTT versus placebo for either probiotic group,
a 20% difference between the two probiotic groups, a
9% attrition rate, a two-sided alpha level of 0.05, and
87% statistical power.
Randomization
Randomization was stratiﬁed by age (25–50 years or
51–65 years) and gender and was implemented using a
permuted block design. Subjects were randomly allo-
cated to one of the three treatment groups within their
age- and gender-stratiﬁcation categories using four
computer-generated randomization lists. The blinded
randomization sequence was generated by a biostatis-
tician at Sprim Advanced Life Sciences, Sprim USA
(San Francisco, CA, USA). The study coordinator at
the investigative site enrolled and assigned subjects to
treatment groups. Study products were labeled with
sequential subject identiﬁcation numbers within each
stratum and were provided to the site by the sponsor.
The site was instructed to enroll subjects consecutively
within the appropriate age/gender stratum.
Blinding
The study was conducted using triple-blinding meth-
ods: subjects, investigators, outcome assessors, study
site personnel, data managers, biostatisticians, and
the sponsor remained blinded to the treatment assign-
ments until data analyses were completed. Study
products were delivered to the investigative site in
identical containers labeled only with the lot number
and subject identiﬁcation codes. All capsules were
identical in appearance, texture, taste, and smell.
Statistical methods
Data were recorded on case report forms and
double-entered into a database that was veriﬁed
Run-in period Intervention period
Day-7 Day-6
Daily consumption of
capsules with
radiopaque markers
Daily consumption of
capsules with
radiopaque markers
Abdominal x-ray, FFQ,
DDQ, begin daily
supplementation
Abdominal x-ray, FFQ,
DDQ,complete daily
supplementation
Day 0 Day 8 Day 14
Figure 1. Timeline of study activities. DDQ = digestive discomfort questionnaire; FFQ = food frequency questionnaire.
B. lactis HN019 and WGTT 1059and independently monitored for accuracy by Sprim
Advanced Life Sciences, Sprim USA. Baseline sub-
ject characteristics for the three treatment groups were
reported using mean and standard deviation for
intervally and ordinally scaled variables and frequen-
cies and percentages for categorical variables. Com-
parisons of change from study days 0–14 across
treatment groups were performed using one-
way analysis of variance (ANOVA). When a resulting
ANOVA p-value was <0.05, post hoc tests were con-
ducted to determine which groups were statistically
different from each other at an alpha level of 0.05.
WGTT was calculated using the formula:
WGTT = n (t/N) i × [,] 15 16
where ni is the number of markers observed on X-ray,
t is the time between marker ingestions in hours, and
N is the total number of markers ingested each day.
Thus, in this study, t/N equals 1 (24 markers per
capsule/24 h between marker ingestions), and WGTT
is therefore equal to the total marker count. Changes
in WGTT between study days 0 and 14 were com-
pared across treatment groups using ANOVA. Anal-
ysis of covariance (ANCOVA) was used to remove the
effect of potentially confounding baseline differences
among the groups and determine the signiﬁcance of
the effect of treatment on WGTT independent of the
potential confounders gender, age, race, and baseline
WGTT. The Kaplan-Meier method was used to
evaluate time to excretion of all markers by treatment
on days 0 and 14 and the signiﬁcance of inter-
group differences was assessed using the Mantel-
Cox test. The Wilcoxon signed-rank test was used
to evaluate changes in gastrointestinal symptom
frequency for each group. Statistical analyses were
performed using BMDP software (Version 8.2,
Statistical Solutions, Saugus, MA, USA).
Results
Participant ﬂow
A total of 100 subjects were enrolled and randomized.
Abdominal X-ray endpoint data were available at days
0 and 14 for 88 subjects (Figure 2). Paired gastroin-
testinal symptom and food frequency data were avail-
able for 87 subjects. All subjects with data for both
study days 0 and 14 were used in the analysis. No
subject withdrawals were related to the study product.
Among subjects who completed the study, compli-
ance with the study product was 100% in each study
group.
Recruitment
Subjects were enrolled in this clinical study between
June 2009 and November 2009 and subject follow-up
continued through December 2009.
Baseline data
Baseline subject characteristics were similar among
the three treatment groups (Table I). Frequency of
consumption of all food categories was, in general,
similar across the treatment groups. Functional gas-
trointestinal symptom frequency was comparable
across groups with constipation, irregular bowel
movements, and ﬂatulence most commonly reported.
Total WGTT was comparable among the three
Assessed for eligibility
(n = 111)
Randomized (n = 100)
High dose (n = 33)
Discontinued (n = 0) Discontinued (n = 7) Discontinued (n = 5)
Analyzed (n = 33) Analyzed (n = 26) Analyzed (n = 29)
Low dose (n = 33) Placebo (n = 34)
Excluded (n = 11)
￿ Did not meet inclusion criteria (n = 11)
Figure 2. CONSORT patient ﬂow diagram. High dose, 17.2 billion CFU Biﬁdobacterium lactis HN019; Low dose, 1.8 billion CFU B. lactis
HN019. CFU = colony forming unit.
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34 h) had a signiﬁcantly longer (p = 0.02) baseline
WGTT versus males (41 ± 24 h) while race and body
mass index had no inﬂuence on WGTT.
Numbers analyzed
A total of 100 subjects were enrolled and randomized.
Of these subjects, 0 in the high dose group, 7 in the
low dose group, and 5 in the placebo group discon-
tinued before the day 14 study visit. All 88 subjects
with WGTT data and 87 subjects with gastrointesti-
nal symptom frequency data for study days 0 and
14 were included in the analysis.
Outcomes and estimation
Food frequency. When changes in food frequency over
the study period were evaluated, each speciﬁc food
type was consumed with comparable frequency across
study groups throughout the study with the exception
of yogurt consumption (data not shown). Since the
study product was consumed in yogurt, the median
yogurt intake signiﬁcantly increased in all three study
groups from never (low dose) or seldom (high dose
and placebo) at day 0 to once a day (all groups) at day
14. Overall, food consumption habits among groups
were similar and likely had no inﬂuence on the
primary study outcomes.
Whole gut transit time
Both B. lactis HN019 groups had a statistically
signiﬁcant decrease in mean WGTT over the
14-day study period (high dose = 33% reduction,
low dose = 25% reduction) with no change obser-
ved in the placebo group (Figure 3). The difference
in WGTT change was statistically signiﬁcant
(p < 0.001) across study groups, thereby representing
a strong dose-response effect of B. lactis HN019
(Table II).
Due to differences in baseline WGTT among the
three treatment groups, an ANCOVA model was used
to examine inter-group differences in WGTT at day
14 adjusted for baseline WGTT differences in order
to minimize possible confounding effects. After con-
trolling for baseline levels, WGTT at day 14 remained
signiﬁcantly different (p = 0.001) among the three
study groups.
Figure 4a shows Kaplan-Meier curves for time
to excretion of all ingested markers at baseline, which
were not signiﬁcantly different among the three
treatment groups. Following 14 days of supplemen-
tation with B. lactis HN019, the high dose group had
Table I. Baseline subject characteristics.
Characteristic High dose (n = 33) Low dose (n = 26) Placebo (n = 29) p
Age, yr (mean ± sd) 43 ± 12 44 ± 11 45 ± 11 0.78
Female gender, n (%) 20 (61) 16 (62) 20 (69) 0.76
Ethnicity, n (%) 0.64
-African American 19 (58) 16 (61) 18 (62)
-Hispanic 7 (21) 7 (27) 4 (14)
-White 6 (18) 3 (12) 7 (24)
-Asian 1 (3) 0 0
Body mass index, kg/m
2 (mean ± sd) 32 ± 83 0 ± 73 2 ± 8 0.73
Whole gut transit time, h (mean ± sd)
-Right colon 17 ± 11 22 ± 15 13 ± 9 0.04
-Left colon 17 ± 15 23 ± 17 17 ± 19 0.18
-Rectosigmoid 15 ± 14 16 ± 11 11 ± 12 0.19
-Total 49 ± 30 60 ± 33 42 ± 31 0.13
GI symptom frequency (mean ± sd)*
-Upper GI symptoms
-Vomiting 14.8 ± 21.7 11.0 ± 20.2 8.0 ± 18.6 0.44
-Regurgitation 30.7 ± 27.7 24.9 ± 28.7 18.4 ± 22.6 0.20
-Abdominal pain 34.6 ± 26.6 43.8 ± 30.6 36.0 ± 29.6 0.44
-Nausea 28.6 ± 24.7 29.9 ± 26.8 23.2 ± 26.8 0.60
-Gurgling 47.7 ± 30.9 45.1 ± 29.4 38.3 ± 26.4 0.45
-Lower GI symptoms
-Constipation 68.7 ± 22.0 75.7 ± 30.4 60.9 ± 32.5 0.16
-Diarrhea 14.8 ± 20.0 9.8 ± 21.9 23.2 ± 31.0 0.13
-Irregular bowel movements 61.7 ± 28.8 61.7 ± 32.0 53.8 ± 36.3 0.57
-Flatulence 59.7 ± 32.8 49.0 ± 32.6 46.7 ± 34.0 0.26
Abbreviations: GI = gastrointestinal; sd = standard deviation; *self-rated on a numeric scale anchored at 1 = never and 100 = always.
B. lactis HN019 and WGTT 1061a signiﬁcantly shorter WGTT than both the low dose
and placebo groups (p < 0.05) (Figure 4b).
Functional gastrointestinal symptom frequency
Statistically signiﬁcant improvements in most gastro-
intestinal symptom frequency scores were reported
between days 0 and 14 in the high and low dose
groups. Most symptoms improved in the high dose
(eight of nine) and low dose (seven of nine) groups,
respectively, while only two of nine symptoms showed
a statistically signiﬁcant improvement with placebo
(Table III). Of particular interest were the changes
in constipation, irregular bowel movements, and ﬂat-
ulence since symptoms were reported with the highest
frequency at baseline. For each of these symptoms,
the relative decrease in symptom frequency was
approximately two-fold greater in the B. lactis
HN019 groups compared to placebo.
Harms
Aside from functional gastrointestinal symptoms
reported on the questionnaire, no adverse events
were reported in any group during the study.
Discussion
This randomized, triple-blind, placebo controlled,
dose-ranging study provides Level I evidence that
dietary consumption of B. lactis HN019 shortens
WGTT in a dose-dependent manner and reduces
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Figure 3. Change in whole gut transit time over 14 days by
study group. Values represent mean ± 95% conﬁdence interval.
High dose, 17.2 billion CFU Biﬁdobacterium lactis HN019; Low
dose, 1.8 billion CFU B. lactis HN019. CFU = colony forming unit.
Table II. Whole gut transit time by treatment group and study day.
Whole gut transit
time
High dose
(n = 33)
Low dose
(n = 26)
Placebo
(n = 29)
Day 0, mean h 49.2 59.5 42.5
95% CI 39.2 to 59.2 46.7 to 72.3 31.3 to 53.7
Min, median, max 0, 49, 135 9, 68, 111 0, 35, 131
Day 14, mean h 21.0 41.0 43.8
95% CI
† -- -
Min, median, max 0, 5, 131 0, 26.5, 141 0, 46, 131
Absolute change,
mean h*
-28.1 -18.5 1.3
95% CI -38.9 to -17.3 -32.3 to -4.6 -5.7 to 8.3
Min, median, max -87, -33, 65 -84, -18, 67 -35, 5, 39
Relative change,
mean %*
-32.6
‡ -24.5 16.7
‡
95% CI
† -- -
Min, median, max -100, -94,
600
-100, -48,
214
-100, 11,
286
Abbreviation: CI = conﬁdence interval; *p < 0.001 among groups;
†CIs were not calculated when distributions were non-normal;
‡relative change could not be calculated for a denominator of 0,
resulting in exclusion of one subject each from the high dose and
placebo groups.
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Figure 4a. Time to radiopaque marker excretion at pre-
treatment by study group. High dose, 17.2 billion CFU Biﬁdobac-
terium lactis HN019; Low dose, 1.8 billion CFU B. lactis HN019.
CFU = colony forming unit.
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Figure 4b. Time to radiopaque marker excretion at 14 days post-
treatment by study group. High dose, 17.2 billion CFU B. lactis
HN019; Low dose, 1.8 billion CFU B. lactis HN019. CFU = colony
forming unit.
1062 P. A. Waller et al.the frequency of functional gastrointestinal symptoms
in adults. In addition, the absence of reported adverse
events suggests that short-term B. lactis HN019
supplementation is safe. The role of probiotics in
inﬂuencing intestinal disturbances, in particular, pre-
venting or shortening the duration of diarrhea in
infants or adults with acute gastroenteritis is well
established [17–20]. The effect of probiotics on intes-
tinal transit has been studied to a limited extent
although, aside from the current trial, no study has
shown an improvement in WGTT.
Several potential mechanisms have been suggested
that may explain the effect of a probiotic strain on
intestinal motility [21,22]. These mechanisms include
an increase in fecal bacterial mass, stimulation of
cholecytokinin, and deconjugation of bile salts result-
ing in free secondary bile salts that can stimulate
colonic motility and excretion. In a small clinical trial
with 32 volunteers, Marteau et al. [22] showed con-
sumption of B. lactis DN-173 010 shortened WGTT
in women aged 18–45 years. This effect was not due
to deconjugation or dehydroxylation of bile salts. The
authors speculated that a product of bacterial origin
may decrease sigmoid tonus and stimulate colonic
motility. Phloroglucinol is one such compound that is
known to have strong effect on colonic motility
[23,24]. However, we did not analyze fecal metabo-
lites in the current study to validate this hypothesis.
Supplementation with B. lactis HN019 has been
shown to increase the level of resident biﬁdobacteria
and lactobacilli and to reduce enterobacteria counts in
adults [13]. This may provide a further potential
mechanism of action for B. lactis HN019 supple-
mentation since increased levels of lactic acid-
producing bacteria may lower the colonic pH and
production of other short-chain fatty acids may stim-
ulate peristalsis and potentially result in a shorter
WGTT [25].
The clinical importance of a short-term decrease in
WGTT is subject to debate. However, it is reasonable
to assume that if long-term probiotic consumption
could chronically lower WGTT, this may potentially
yield a meaningful decrease in the risk of associated
colorectal conditions, such as colon cancer. The
beneﬁcial effect of daily B. lactis HN019 on WGTT
is at least equivalent to that of dietary ﬁber. However,
unlike ﬁber, B. lactis HN019 also improves gastroin-
testinal symptoms [26–28]. Furthermore, B. lactis
HN019 is safe for human consumption as no
untoward side effects associated with the product
have been reported, a ﬁnding that is well established
including data from studies with infants to elderly
[12,29].
Subjects in the present study suffered from func-
tional gastrointestinal symptoms with constipation,
irregular bowel movements, and ﬂatulence as the
predominant symptoms. The outcomes of this study
suggest that B. lactis HN019 supplementation reduces
the frequency of many common upper and lower
gastrointestinal symptoms. Since these symptoms
are generally non-speciﬁc, management strategies
are narrowly focused on the treatment of individual
symptoms. B. lactis HN019 is potentially advan-
tageous since this single product may be used to
alleviate multiple gastrointestinal symptoms simulta-
neously. Although the present study utilized capsules,
fermented and non-fermented dairy products are an
ideal matrix for the inclusion and consumption of B.
lactis HN019.
The present study has several strengths including
randomized treatment allocation, use of placebo con-
trols, assessment of dose ranging efﬁcacy, evaluation
of dietary intake during the study, and use of stringent
data collection and blinding methods. This study also
had several limitations. The results presented herein
are applicable only to B. lactis HN019 and cannot be
generalized to other probiotic strains or products.
Caution should be exercised in extrapolating these
study outcomes to people with chronic and/or severe
gastrointestinal complications. A ﬁnal limitation of
the study was that almost one in three subjects in the
probiotic groups had no observable markers on
follow-up radiographs, which indicated a WGTT of
less than 24 h. However, according to the formula
used to calculate WGTT [15,16], these subjects were
assigned a WGTT of 0 h, a value that is physiolog-
ically impossible. Nevertheless, the conclusions of this
trial are valid since nonparametric statistical methods
corroborated the ﬁndings of the primary analysis.
In conclusion, consumption of the probiotic
B. lactis HN019 is well tolerated, decreases WGTT
Table III. Mean absolute change in GI symptom frequency score
over the 14-day supplementation period.
Symptom*
High dose
(n = 33)
Low dose
(n = 26)
Placebo
(n = 28)
Upper GI symptoms
Vomiting -9.8* -7.4 -2.2
Regurgitation -14.9* -11.3* -2.3
Abdominal pain -17.9
† -26.6
‡ -8.2
Nausea -13.8* -13.8
† -3.5
Gurgling -12.9* -23.9
‡ -4.7
Lower GI symptoms
Constipation -29.0
‡ -35.8
‡ -14.2*
Diarrhea -2.9 0.0 -9.4*
Irregular bowel movements -19.0
† -22.8
† -9.5
Flatulence -14.0* -15.3* -5.9
Abbreviation: GI = gastrointestinal; *self-rated on a numeric scale
anchored at 1 = never and 100 = always; *p < 0.05,
†p < 0.01,
‡p < 0.001.
B. lactis HN019 and WGTT 1063in a dose-dependent manner, and reduces the
frequency of functional gastrointestinal symptoms
in adults.
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